ABOUT IMMUNO CURE

About Immuno Cure

Immuno Cure is a biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-based DNA vaccine and Anti-PD-1 Isoform Antibody technology platforms.

Milestones

2015

Immuno Cure Limited was formed in Hong Kong, China

2016

Exclusive license and collaboration agreement was signed with The University of Hong Kong Technology Transfer Office (HKU TTO) for ICVAX

2017

Shenzhen Immuno Cure Biotechnology Limited (深圳医克生物科技有限公司) was established in Shenzhen, China

2018

Exclusive license and collaboration agreement was signed with HKU TTO for Anti-PD-1 Isoform Antibody

2019

Engaged a GMP manufacturer and a GLP laboratory for vaccine manufacturing, animal efficacy and safety evaluation of ICVAX

2020

1. Exclusive license agreement was signed with HKU TTO for ICCOV

2. Engagement of a GMP manufacturer and a GLP laboratory for manufacturing and animal tests of ICCOV

2021 

Apr

1. IND enabling stage of ICVAX and ICCOV

2. Setup R&D Laboratory in HK Science Park

2021

May

Completion of Seed 2 round fundraising

2021 November

Collaboration with HKU and obtained approval from Department of Health for conducting phase 1 clinical trial of ICCOV in HK Queen Mary Hospital

2021

December

Acquisition of a HKSTP company - Pure Innovation Biotech Limited, to develop the plasmid delivery technology and DNA vaccine manufacturing process technology

Our Team

Strategic Partners

Self Photos / Files - Strategic Partnerships grey V4(IV)_20211216